•							
Page 1 of 2 Pages	[X] Original	[] Substitute	[] Supplemental	Atty. Docket:	YAYONII		
Combined Declaration for Patent Application and Power of Attorney							
	nventor, I hereby declare th						
and sole inventor (it subject matter which	office address and citizensh fonly one name is listed be a is claimed and for which a	low) or an original patent is sought or	, first and joint inventor the invention entitled				
TREATMENT OF The specification of	CELL MEDIATED DISE	ASES BY INHIBI	TION OF FGFR3		 		
[]	is attached hereto;						
i i	was filed in the United Sta		C. §111 on	, as			
[X]	U.S. Appln. No	I.S. under 35 U.S.C IL2004/000528; fil ation received	ed June 17, 2003, entr	y requested on	December 19, 2005*;		
and was amended or	1		(if app	licable).			
	(include dates of amendme	nts under PCT Art. 1	9 and 34 if PCT)				
amendment referred	d understand the contents to above; and I acknowled naterial to patentability as o	lge the duty to disc	close to the Patent and T				
I hereby claim forei inventor's or plant to other than the U.S.,	gn priority benefits under 3 preeder's rights certificate(s) listed below:	5 U.S.C. §§ 119 (a), or under §365(a)	a)-(d) and 365 (b) of any of any PCT application	y prior foreign ap n which designate	plication(s) for patent, ed at least one country		
	Application No.	Country	Filing Date	(MM/DD/YYYY)			
	156495	Israel	06/17/2003		_		
application designat date before that of the	priority above, I hereby id ing a country other than the earliest application from von-Priority Application No.	e United States) or	for an inventor's or plity is claimed (if left bla	ant breeder's certi	ficate, having a filing none):		
I hereby claim the be	enefît under 35 U.S.C. §119	(e) of any United S	tates provisional application	ations listed below	 /:		
Application No. Filing Date (MM/DD/YYYY)							
	60/499,9		07/30/2003	<u>-</u> -			
I hereby claim the b	enefit under 35 U.S.C. §12	20 of any prior U.S	S. non-provisional appli	cation(s) or under	§365(c) of any prior		

I hereby claim the benefit under 35 U.S.C. §120 of any prior U.S. non-provisional application(s) or under §365(c) of any prior PCT international application(s) designating the U.S., listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in such U.S. or PCT international application in the manner provided by the first paragraph of 35 U.S.C. §112, I acknowledge the duty to disclose to the PTO all information which is material to patentability as defined in 37 C.F.R. §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

Application No. Filing Date (MM/DD/YYYY) Status (patented, pending, abandoned)

As a named inventor, I hereby appoint the following registered practitioners to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

All of the practitioners associated with Customer Number 001444

Direct all correspondence to the address associated with Customer Number 001444, which is presently:

BROWDY AND NEIMARK, P.L.L.C. 624 Ninth Street, N.W. Washington, D.C. 20001-5303 (202) 628-5197

U.S. Application filed	, Serial No.		
U.S. Application filed PCT Application filed	, Serial No		
The undersigned hereby authorizes the U.S. Attorneys of PROCHONE BIOTECH LTD. as to any action to be to without direct communication between the U.S. Attorney from whom instructions may be taken, the U.S. Attorney	aken in the U.S. Patent and Trac ys or Agents and the undersigned s or Agents appointed herein will	lemark Office regonant in the event of be so notified by	garding this application a change of the persons the undersigned.
I hereby further declare that all statements made herein of and belief are believed to be true; and that these statem like so made are punishable by fine or imprisonment, or jeopardize the validity of the application or any patent is	nents were made with the knowle r both, under 18 U.S.C. §1001 ar	dge that willful f	false statements and the
FULL NAME OF FIRST INVENTOR	INVENTOR'S SIGNATURE		DATE
Avner YAYON	1 Ann Par		Z. 16. Z006
RESIDENCE Moshav Sitria, Israel		CITIZENSHIP Israel	
POST OFFICE ADDRESS			
Sitria 104, 76834 Moshav Sitria, Israel			
FULL NAME OF SECOND JOINT INVENTOR	INVENTOR'S SIGNATURE		DATE
RESIDENCE		CITIZENSHIP	
POST OFFICE ADDRESS			
FULL NAME OF THIRD JOINT INVENTOR	INVENTOR'S SIGNATURE		DATE
RESIDENCE		CITIZENSHIP	
POST OFFICE ADDRESS			
FULL NAME OF FOURTH JOINT INVENTOR	INVENTOR'S SIGNATURE		DATE
RESIDENCE		CITIZENSHIP	
POST OFFICE ADDRESS			
FULL NAME OF FIFTH JOINT INVENTOR	INVENTOR'S SIGNATURE		DATE
RESIDENCE		CITIZENSHIP	
POST OFFICE ADDRESS			
FULL NAME OF SIXTH JOINT INVENTOR	INVENTOR'S SIGNATURE		DATE
RESIDENCE		CITIZENSHIP	
POST OFFICE ADDRESS			

Atty. Docket: YAYON11

Page 2 of 2 Pages
Title: TREATMENT OF T CELL MEDIATED DISEASES BY INHIBITION OF FGFR3

ALL INVENTORS MUST REVIEW APPLICATION AND DECLARATION BEFORE SIGNING. ALL ALTERATIONS MUST BE INITIALED AND DATED BY ALL INVENTORS PRIOR TO EXECUTION. NO ALTERATIONS CAN BE MADE AFTER THE DECLARATION IS SIGNED. ALL PAGES OF DECLARATION MUST BE SEEN BY ALL INVENTORS.